Baseline laboratory panel: difference between revisions
Diff·revision 15 → 16·13:34, 26 May 2025
Difference between revision 15 and revision 16 of Baseline laboratory panel. 6 lines changed; the page grew by 680 bytes.
| Revision 15 — 04:21, 8 May 2025 ApoB_Aurelio (talk) expand §Interpretation over time 3,542 bytes +16 | Revision 16 — 13:34, 26 May 2025 SPPS_Sorrel (talk) fix indentation in the source 4,222 bytes +680 | ||
|---|---|---|---|
| 34 | Regression to the mean operates on any value selected for being extreme. A repeat measurement after an abnormal one tends to be closer to the mean whether or not anything was done in between — which is why a single abnormal value is weaker evidence than a trend.{{r|hrobjartsson2010}} | 34 | Regression to the mean operates on any value selected for being extreme. A repeat measurement after an abnormal one tends to be closer to the mean whether or not anything was done in between — which is why a single abnormal value is weaker evidence than a trend.{{r|hrobjartsson2010}} |
| 35 | 35 | ||
| + | 36 | == Interpretation over time == | |
| + | 37 | The useful output of a baseline is a trajectory. A single follow-up value tells less than a series, and a series on a consistent platform tells more than a longer series across several.{{r|ada2024}} | |
| + | 38 | ||
| + | 39 | Some analytes move quickly and some slowly. [[Haemoglobin A1c|Glycated haemoglobin]] reflects roughly the preceding three months and cannot show a change over three weeks; lipids respond within weeks; body-weight-associated changes follow the weight.{{r|drucker2018}} | |
| + | 40 | ||
| 36 | == References == | 41 | == References == |
| 37 | {{reflist}} | 42 | {{reflist}} |
| ⋮ | ⋮ | ||
| 39 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). PMID 15161807.</ref> | 44 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). PMID 15161807.</ref> |
| 40 | <ref name="hrobjartsson2010">Hróbjartsson A, Gøtzsche PC. "Placebo interventions for all clinical conditions." ''Cochrane Database of Systematic Reviews'' (1):CD003974 (2010). PMID 20091554.</ref> | 45 | <ref name="hrobjartsson2010">Hróbjartsson A, Gøtzsche PC. "Placebo interventions for all clinical conditions." ''Cochrane Database of Systematic Reviews'' (1):CD003974 (2010). PMID 20091554.</ref> |
| + | 46 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 41 | 47 | ||
| 42 | == See also == | 48 | == See also == |